What is Gamida Cell Cash, Cash Equivalents, Marketable Securities?
Gamida Cell‘s quarterly cash, cash equivalents, marketable securities
declined
from Sep. 2023 ($60.43 Mil) to Dec. 2023 ($46.55 Mil) but then
stayed the same
from Dec. 2023 ($46.55 Mil) to Mar. 2024 ($24.78 Mil).
Gamida Cell‘s annual cash, cash equivalents, marketable securities
declined
from Dec. 2021 ($95.93 Mil) to Dec. 2022 ($64.66 Mil) and
declined
from Dec. 2022 ($64.66 Mil) to Dec. 2023 ($46.55 Mil).
Gamida Cell Cash, Cash Equivalents, Marketable Securities Historical Data
The historical data trend for Gamida Cell‘s Cash, Cash Equivalents, Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company’s associated stock exchange currency.
Gamida Cell Cash, Cash Equivalents, Marketable Securities Chart
Gamida Cell Cash, Cash Equivalents, Marketable Securities Calculation
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.
Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Gamida Cell Cash, Cash Equivalents, Marketable Securities Related Terms
Thank you for viewing the detailed overview of Gamida Cell’s Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.
Gamida Cell Business Description
Traded in Other Exchanges
N/A
Address
116 Huntington Avenue, 7th Floor, Boston, MA, USA, 02116
Gamida Cell Ltd is a clinical-stage biopharmaceutical company that is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumors and blood cancers and other serious blood diseases. The company applies a proprietary expansion platform leveraging the properties of nicotinamide, or NAM, to allogeneic cell sources including umbilical cord blood-derived cells and natural killer, or NK, cells to create cell therapy candidates with the potential to redefine standards of care. Its primary product candidate is Omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant and GDA-201 is the company’s lead investigational NK cell-based cancer immunotherapy product candidate.
Executives
| Jeremy Blank | director | 6446 DREXEL AVENUE, LOS ANGELES CA 90048 |
| Mary Theresa Coelho | officer: Chief Financial Officer | 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017 |
| Ronit Simantov | officer: CMO & Chief Scientific Officer | 1988 CHAPEL STREET, NEW HAVEN CT 06515 |
| Abigail L. Jenkins | director, officer: President and CEO | C/O GAMIDA CELL LTD., 116 HUNTINGTON AVENUE, BOSTON MA 02116 |
| Stephen T Wills | director | PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
| Ivan M. Borrello | director | C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340 |
| Anat Cohen-dayag | director | C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340 |
| Naama Halevi-davidov | director | C/O KALTURA, INC., 250 PARK AVENUE SOUTH, 10TH FLOOR, NEW YORK NY 10003 |
| Joshua F. Patterson | officer: General Counsel | C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210 |
| Bio Medical Investment (1997) Ltd. | other: Affiliate of 10% Owner | 3 AZRIELI CENTER TRIANGLE, TOWER,, 45TH FLOOR, 132 MENACHEM BEGIN ST., TEL AVIV L3 6702301 |
| Shai Lankry | officer: Chief Financial Officer | C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340 |
| Ai Gamida Holdings Llc | other: Affiliate of 10% Owner | 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019 |
| Ofer Gonen | director | 1/3 HIGH-TECH VILLAGE, GIVAT RAM, P.O. BOX 39264, JERUSALEM L3 9139102 |
| Clal Biotechnology Industries Ltd. | other: Affiliate of 10% Owner | 3AZRIELI CENTER TRIANGLE TOWER 45 FLOOR, TEL AVIV L3 67023 |
| Len Blavatnik | 10 percent owner | C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019 |
